Gaush Meditech Announces 2025 Annual Results: Gross Profit Surges 33.8% Amid Strong Global Expansion

Gaush Meditech (2407.HK) has reported its annual results for 2025, demonstrating robust growth across the board. The company achieved a total revenue of RMB 1.380 billion, while gross profit surged 33.8% year-over-year to reach RMB 144 million. All three core business segments delivered solid performance: medical equipment revenue rose 18.9% to RMB 668 million, consumables grew 15.5% to RMB 614 million, and technical services increased 18.1% to RMB 92.58 million.

Driven by continuous innovation, Gaush dedicated 21.6% of its revenue to R&D, accumulating 153 patents. The company's global footprint continues to expand rapidly, now covering over 50 countries and regions. The service network currently supports more than 5,000 end customers with an installed equipment base exceeding 29,000 units. Moving forward, Gaush Meditech will deepen its strategy of "heavy R&D, broad coverage, and strong connections" to further advance global ophthalmic healthcare.